Levemir | ASweetLife

Novo Nordisk’s Levemir Insulin Approved for Use in Children as Young as Two

The U.S. Food and Drug Administration (FDA) has approved Levemir (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes, making it the first and only basal insulin analog for use in this young patient group. With the expansion of its pediatric indication...

Using Insulin in Pregnancy: FDA Approves Levemir

Dr. Jovanovic even recommends using Levemir injections at night to women using insulin pumps, as she prefers the assurance of a basal shot...

FDA Approves Novo Nordisk’s Levemir Insulin for Pregnant Women with Diabetes

The U.S. FDA has approved Novo Nordisk's Levemir insulin (insulin detemir [rDNA origin] injection) for use by pregnant women with diabetes, giving it a Category B classification, indicating that it does not increase the risk of harm to the unborn baby. The label update makes Levemir the first and only basal insulin analog to have this classification...

Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients

Following a review of new data from a 52-week clinical trial, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir, as add-on therapy to Novo Nordisk’s GLP-1 analogue, Victoza, in combination with metformin in patients with type 2 diabetes...

Levemir Better for Treating Young Children with Type 1 Diabetes Than Human Basal Insulin

New clinical trial data just published in Pediatric Diabetes shows that Levemir (insulin detemir), Novo Nordisk’s basal insulin analogue, is an equally efficacious treatment option for two to five year-old children with type 1 diabetes, compared with human basal insulin, but is associated with lower hypoglycemic risk. Children with type 1 diabetes who are aged under six years...

Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients

Novo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (ADA) 2010 Scientific Sessions, demonstrated a reduction of A1c levels in type 2 diabetes patients when a dose of NovoLog® was introduced at meals, using two approaches that start with the largest meal of...